Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerability of Ribavirin (RO 20-9963) in Combination With Peginterferon Alfa-2a (40 kD)in Patients With Chronic Hepatitis C

NCT00922779 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00922779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00922779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerability of Ribavirin (RO 20-9963) in Combination With Peginterferon Alfa-2a (40 kD)in Patients With Chronic Hepatitis C
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2002
Completion date
June 30, 2012
Enrollment
6,661 (actual)
Sites
93

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic